Achieve Life Sciences (ACHV) EBITDA Margin (2010 - 2015)

Achieve Life Sciences' (ACHV) quarterly EBITDA Margin came in at 20.35% in Q4 2015, down 105.6% on a QoQ basis from 363.15% in Q4 2012.

Achieve Life Sciences (ACHV) EBITDA Margin (2010 - 2015) Analysis & Trends

Achieve Life Sciences (ACHV) has 4 years of EBITDA Margin data on file, last reported at 20.35% in Q4 2015.

Quarterly EBITDA Margin changed N/A year-over-year to 20.35% in Q4 2015, while the trailing twelve-month figure through Dec 2015 was 267.2% (changed N/A YoY) and the FY2015 annual result came in at 2.16%, changed N/A from the prior year.
EBITDA Margin slipped to 20.35% in Q4 2015, from 363.15% in the prior quarter.
In the past five years, EBITDA Margin ranged from a high of 363.15% in Q4 2012 to a low of 7012.62% in Q4 2011.
A 3-year average of 726.59% and a median of 126.18% in 2012 frame the typical range for EBITDA Margin.
Annual changes were most pronounced in 2011 — EBITDA Margin plunged 689266 bps — and 2012, when it jumped 737577 bps.
Tracing ACHV's EBITDA Margin over 3 years: stood at 7012.62% in 2011, then surged by 105 bps to 363.15% in 2012, then sank by 106 bps to 20.35% in 2015.
The last three EBITDA Margin figures came in at 20.35% (Q4 2015), 363.15% (Q4 2012), and 126.18% (Q3 2012), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	30.15%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	31.68%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	19.06%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-77,569,866.34%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	19.75%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	17.93%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.36%
10	Achieve Life Sciences	330.88 Mn	330.88 Mn	-	-

Download Data